Catalyst Biosciences to Host Research and Development Day on CB 4332 and Complement Programs
July 01 2021 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it
will host a research and development day on its protease medicines
platform focusing on the regulation of complement including CB 4332
on Monday, July 19, 2021 at 12:00 pm Eastern Time.
The Catalyst Biosciences R&D Day will
feature a presentation by Key Opinion Leader (KOL) Filomeen
Haerynck, M.D., Ph.D., University of Ghent, Belgium, who will
discuss the clinical phenotype, current treatment landscape and
unmet medical need in treating patients with complement factor I
(CFI) deficiency and other complement system disorders.
The event will also feature a presentation by
Catalyst Biosciences' management team on the company’s upcoming
clinical trial and the benefits of addressing the complement
pathway with its protease medicines platform.
The Catalyst team will discuss the planned
commencement of screening and natural history of disease studies in
mid-2021 followed by a Phase 1/2 study for CB 4332 in 2022. The
screening study is designed to identify people with a CFI
deficiency by assessing circulating levels of CFI. The natural
history of disease study will follow up and assess these patients
for clinical outcomes, biomarkers of complement dysregulation as
well as safety and effectiveness of their current treatments in
preparation for the clinical development program of CB 4332.
Catalyst’s complement portfolio is led by the
development candidates CB 4332 and CB 2782-PEG, originating from
the company’s internal discovery platform, which has generated a
rich pipeline of leads. CB 4332 is an engineered CFI protease with
the potential to become a therapy addressing multiple complement
related disorders. CB 2782-PEG is a potential best-in-class C3
degrader product candidate in preclinical development for the
treatment of dry AMD that Catalyst has licensed to Biogen. Catalyst
has several engineered protease programs in discovery or early
non-clinical development. These programs all target diseases caused
by deficient regulation of the complement system.
To register for the research and development
day, please click here.
Prof. Filomeen Haerynck has worked since 2002 as
a pediatric lung specialist and immunologist in the department of
pediatric pulmonary diseases, infectious diseases and primary
immune disorders at Ghent University Hospital Ghent, Belgium. She
specialized in primary immune disorders in Hôpital Necker (Prof. A.
Fischer), Paris (2005). In 2014, she obtained her doctorate in
medical sciences with her thesis on 'Innate Immunity in Chronic
Infectious and Inflammatory Diseases'. Prof. Haerynck is treating
children with primary immune disorders (PID) who present with
recurrent, invasive infections and/or uncontrolled inflammation and
lymphoproliferation. Prof. Haerynck is coordinator of Centre of
Primary Immune deficiency Ghent (CPIG), recognized as an
international Jeffrey Modell Diagnostic and Research Centre and one
of the largest centers specialized in PID in Belgium. She is
Principal Investigator of the PID research lab (PIRL) conducting
translational scientific research in PID patients. She is also
collaborator in the international COVID Human Genetic Efforts
Consortium, led by Prof. Jean-Laurent Casanova (Rockefeller
Institute) studying why young, healthy patients still become
seriously ill from COVID-19 in some cases. The renowned journal
Science published the paper on this topic in September 2020.
An archived webcast of the presentations will be
available for 90 days on the Events and
Presentations section of the Company’s website.
About Catalyst Biosciences, the Protease
Medicines companyCatalyst is a research and clinical
development biopharmaceutical company focused on addressing unmet
medical needs in rare disorders of the complement and coagulation
systems. Our protease engineering platform has generated two
late-stage clinical programs, including MarzAA, a subcutaneously
(SQ) administered next-generation engineered coagulation Factor
VIIa (FVIIa) for the treatment of episodic bleeding in subjects
with rare bleeding disorders. Our complement pipeline includes a
preclinical C3-degrader program licensed to Biogen for dry
age-related macular degeneration, an improved complement factor I
protease for SQ replacement therapy in patients with CFI deficiency
and C4b-degraders designed to target disorders of the classical
complement pathway as well as other complement programs in
development.
Forward-Looking StatementsThis
press release contains forward-looking statements that involve
substantial risks and uncertainties. Forward-looking statements
include statements about the commencement, timing and anticipated
results of the planned screening study for CFI deficient patients,
clinical development plans for CB 4332 and its potential to treat
multiple complement related disorders, the potential for CB
2782-PEG as a best-in-class C3 degrader, and the Company’s
collaboration with Biogen for the development and commercialization
of CB 2782-PEG for dry age-related macular degeneration. Actual
results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially, including, but not
limited to, the risk that trials and studies may be delayed as a
result of COVID-19, competitive products and other factors, that
trials may not have satisfactory outcomes, that additional human
trials will not replicate the results from earlier trials, the risk
that costs required to develop or manufacture the Company's
products will be higher than anticipated, including as a result of
delays in trial enrollment, development and manufacturing resulting
from COVID-19 and other factors, the risk that Biogen will
terminate Catalyst's agreement, the risk that potential adverse
effects may arise from the testing or use of MarzAA, including the
generation of neutralizing antibodies, competition and other risks
described in the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on May 6, 2021, and in other filings with
the Securities and Exchange Commission. The Company does not
assume any obligation to update any forward-looking statements,
except as required by law.
Contact:
Ana KaporCatalyst Biosciences, Inc.investors@catbio.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024